Xenon Pharmaceuticals Inc. (XENE) stock
XENENasdaqPharmaceutical PreparationsFiscal year ends December 31
$37.04−0.52 (-1.38%)
Close on Nov 20, 2026Market cap $3.59BP/E –Yield –
Xenon Pharmaceuticals free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Xenon Pharmaceuticals's free cash flow for the twelve months ending Jun 30, 2026 was -$338.53M. For fiscal 2025 it was -$279.92M. The highest annual figure on record is $45.05M in fiscal 2012.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$279.92M | – |
| FY2024 | Dec 31, 2024 | -$184.46M | – |
| FY2023 | Dec 31, 2023 | -$156.73M | – |
| FY2022 | Dec 31, 2022 | -$103.92M | – |
| FY2021 | Dec 31, 2021 | -$71.55M | – |
| FY2020 | Dec 31, 2020 | -$50.76M | – |
| FY2019 | Dec 31, 2019 | -$5.95M | – |
| FY2018 | Dec 31, 2018 | -$35.23M | – |
| FY2017 | Dec 31, 2017 | -$29.04M | – |
| FY2016 | Dec 31, 2016 | -$19.85M | – |
| FY2015 | Dec 31, 2015 | -$18.65M | – |
| FY2014 | Dec 31, 2014 | -$1.26M | – |
| FY2013 | Dec 31, 2013 | -$3.48M | -107.7% |
| FY2012 | Dec 31, 2012 | $45.05M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$95.67M | – |
| Q1 FY2026 | Mar 31, 2026 | -$89.03M | – |
| Q4 FY2025 | Dec 31, 2025 | -$81.80M | – |
| Q3 FY2025 | Sep 30, 2025 | -$72.03M | – |
| Q2 FY2025 | Jun 30, 2025 | -$64.39M | – |
| Q1 FY2025 | Mar 31, 2025 | -$61.70M | – |
| Q4 FY2024 | Dec 31, 2024 | -$55.17M | – |
| Q3 FY2024 | Sep 30, 2024 | -$50.26M | – |
| Q2 FY2024 | Jun 30, 2024 | -$32.67M | – |
| Q1 FY2024 | Mar 31, 2024 | -$46.38M | – |
| Q4 FY2023 | Dec 31, 2023 | -$35.48M | – |
| Q3 FY2023 | Sep 30, 2023 | -$49.28M | – |
| Q2 FY2023 | Jun 30, 2023 | -$35.35M | – |
| Q1 FY2023 | Mar 31, 2023 | -$36.62M | – |
| Q4 FY2022 | Dec 31, 2022 | -$37.08M | – |
| Q3 FY2022 | Sep 30, 2022 | -$30.79M | – |
| Q2 FY2022 | Jun 30, 2022 | -$17.41M | – |
| Q1 FY2022 | Mar 31, 2022 | -$18.64M | – |
| Q4 FY2021 | Dec 31, 2021 | -$21.22M | – |
| Q3 FY2021 | Sep 30, 2021 | -$15.23M | – |
| Q2 FY2021 | Jun 30, 2021 | -$13.99M | – |
| Q1 FY2021 | Mar 31, 2021 | -$21.11M | – |
| Q4 FY2020 | Dec 31, 2020 | -$13.94M | -172.6% |
| Q3 FY2020 | Sep 30, 2020 | -$11.95M | – |
| Q2 FY2020 | Jun 30, 2020 | -$11.16M | – |
| Q1 FY2020 | Mar 31, 2020 | -$13.71M | – |
| Q4 FY2019 | Dec 31, 2019 | $19.19M | – |
| Q3 FY2019 | Sep 30, 2019 | -$7.10M | – |
| Q2 FY2019 | Jun 30, 2019 | -$9.01M | – |
| Q1 FY2019 | Mar 31, 2019 | -$9.03M | – |
| Q4 FY2018 | Dec 31, 2018 | -$7.41M | – |
| Q3 FY2018 | Sep 30, 2018 | -$13.74M | – |
| Q2 FY2018 | Jun 30, 2018 | -$5.68M | – |
| Q1 FY2018 | Mar 31, 2018 | -$8.40M | – |
| Q4 FY2017 | Dec 31, 2017 | -$6.90M | – |
| Q3 FY2017 | Sep 30, 2017 | -$8.64M | – |
| Q2 FY2017 | Jun 30, 2017 | -$6.90M | – |
| Q1 FY2017 | Mar 31, 2017 | -$6.60M | – |
| Q4 FY2016 | Dec 31, 2016 | -$4.70M | – |
| Q3 FY2016 | Sep 30, 2016 | -$4.57M | – |
See a number that looks wrong?